Akebia Therapeutics, Inc. Balance Sheet
AKBA|10 years of annual SEC 10-K data (FY2014-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 10 fiscal years. All figures from audited SEC 10-K filings.
Akebia Therapeutics, Inc. had $377M in total assets and $33M in shareholders' equity as of FY2025. Total debt was $48M against $185M in cash, resulting in a $137M net cash position.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -2.76 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $184.8M | $51.9M | $42.9M | $90.5M | $228.7M | $147.4M | $70.2M | $187.3M | $21.2M | $1.6M |
| Accounts Receivable | $47.0M | $34.4M | $39.3M | $40.3M | $50.9M | $26.9M | $38.9M | $16.7M | - | $48.0K |
| Inventory | $15.6M | $16.2M | $15.7M | $21.6M | $38.2M | $61.0M | $116.3M | $114.2M | - | - |
| Current Assets | $253.0M | $113.8M | $118.1M | $185.2M | $272.0M | $371.4M | $309.5M | $468.3M | $141.0M | $110.5M |
| PP&E (Net) | $1.2M | $2.2M | $3.6M | $5.2M | $6.8M | $8.6M | $10.4M | $8.0M | $540.0K | $209.9K |
| Goodwill | $59.0M | $59.0M | $59.0M | $59.0M | $55.1M | $55.1M | $55.1M | $55.1M | - | - |
| Total Assets | $376.6M | $220.7M | $241.7M | $356.1M | $525.5M | $644.1M | $771.2M | $996.5M | $142.9M | $111.0M |
| Current Liabilities | $162.9M | $80.9M | $99.9M | $129.5M | $256.5M | $187.1M | $208.1M | $265.7M | $11.9M | $6.9M |
| Total Debt | $48.3M | $38.7M | $34.7M | $66.1M | $0 | $96.4M | $75.8M | - | - | - |
| Shareholders' Equity | $32.6M | -$49.2M | -$30.6M | $5.2M | $394.8M | $635.9M | $122.6M | $68.1M | -$127.1M | -$59.6M |